source
- Azalea Therapeutics wins Endpoints 11 award, combines gene editing with CAR-T and raises $82 millionAzalea Therapeutics was named the winner of the Endpoints 11 2026 competition, highlighting its innovative approach in the biotech space. The company’s platform merges precise gene‑editing techniq…
- FDA approves Mirum's Atebrioz for ultra-rare disease that hardens muscle and connective tissueThe U.S. Food and Drug Administration has granted approval for Mirum Pharmaceuticals' new therapy for an ultra-rare genetic disorder that causes muscle and connective tissue to turn into bone. The…